PET measurement of serotonin transporter occupancy: A comparison of escitalopram and citalopram

International Journal of Neuropsychopharmacology

Volumn 10, Issue 6, 2007, Pages 777-785

  Lundberg, Johan ^a,c   Christophersen, Jacob Strøyer ^b   Petersen, Kamilla Buchberg ^b   Loft, Henrik ^b   Halldin, Christer ^a   Farde, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b H LUNDBECK A S   (Denmark)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

5 HTT; 11C MADAM; Escitalopram; Human; PET

Indexed keywords

CITALOPRAM; ESCITALOPRAM; SEROTONIN TRANSPORTER;

ADULT; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BINDING; DRUG INHIBITION; ENANTIOMER; HUMAN; IN VIVO STUDY; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIDEPRESSIVE AGENTS; BENZYLAMINES; BRAIN; CITALOPRAM; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35248895978     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145706007486     Document Type: Article

References (36)

1. Andree B, Hedman A, Thorberg SO, Nilsson D, Halldin C, Farde L (2003). Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain. Psychopharmacology (Berlin) 167, 37-45.
2. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, Frazer A (1999). Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. Journal of Neuroscience 19, 10494-10501.
3. Bergstrom M, Boethius J, Eriksson L, Greitz T, Ribbe T, Widen L (1981). Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. Journal of Computer Assisted Tomography 5, 136-141.
4. Burke WJ (2002). Escitalopram. Expert Opinion on Investigational Drugs 11, 1477-1486.
5. Burke WJ, Gergel I, Bose A (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. Journal of Clinical Psychiatry 63, 331-336.
6. Chen F, Larsen MB, Sanchez C, Wiborg O (2005). The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. European Neuropsychopharmacology 15, 193-198.
7. Cohen Z, Bonvento G, Lacombe P, Hamel E (1996). Serotonin in the regulation of brain microcirculation. Progress in Neurobiology 50, 335-362.
8. Colonna L, Andersen HF, Reines EH (2005). A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Current Medical Research and Opinion 21, 1659-68.
9. Farde L (1996). The advantage of using positron emission tomography in drug research. Trends in Neurosciences 19, 211-214.
10. Farde L, Wiesel FA, Halldin C, Sedvall G (1988). Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry 45, 71-76.
11. Gutierrez MM, Rosenberg J, Abramowitz W (2003). An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir. Clinical Therapeutics 25, 1200-1210.
12. 11)C]MADAM, a new serotonin transporter radioligand characterized in the monkey brain by PET. Synapse 58, 173-183.
13. Hyttel J, Bogeso KP, Perregaard J, Sanchez C (1992). The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. Journal of Neural Transmission (General Section) 88, 157-160.
14. 123)I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berlin) 188, 263-272.
15. Lammertsma AA, Hume SP (1996). Simplified reference tissue model for PET receptor studies. Neuroimage 4, 153-158.
16. Lepola UM, Loft H, Reines EH (2003). Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. International Clinical Psychopharmacology 18, 211-217.
17. 11C]MADAM: a test-retest reproducibility study. Synapse 60, 256-263.
18. 11C]MADAM binding to the serotonin transporter in the human brain. Journal of Nuclear Medicine 46, 1505-1515.
19. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P (1997). Multimodality image registration by maximization of mutual information. IEEE Transactions on Medical Imaging 16, 187-198.
20. 11C]DASB positron emission tomography study. American Journal of Psychiatry 161, 826-835.
21. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ (1984). A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Annals of Neurology 15, 217-227.
22. Montgomery SA, Loft H, Sanchez C, Reines EH, Papp M (2001). Escitalopram (S-enantiomer of citalopram) : clinical efficacy and onset of action predicted from a rat model. Pharmacology & Toxicology 88, 282-286.
23. Moore N, Verdoux H, Fantino B (2005). Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. International Clinical Psychopharmacology 20, 131-137.
24. Mork A, Kreilgaard M, Sanchez C (2003). The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 45, 167-173.
25. Owens MJ, Knight DL, Nemeroff CB (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biological Psychiatry 50, 345-350.
26. Rochat B, Amey M, Baumann P (1995). Analysis of enantiomers of citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Therapeutic Drug Monitoring 17, 273-279.
27. Roland PE, Graufelds C, Wählin J, Ingelman L, Andersson M, Ledberg A, Pedersen J, Åkerman S, Dabringhaus A, Zilles K (1994). Human brain atlas : for high-resolution functional and anatomical mapping. Human Brain Mapping 1, 173-184.
28. Sanchez C (2003). R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. European Journal of Pharmacology 464, 155-158.
29. Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C (2004). Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berlin) 174, 163-176.
30. Sanchez C, Gruca P, Bien E, Papp M (2003a). R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacology, Biochemistry, and Behavior 75, 903-907.
31. Sanchez C, Gruca P, Papp M (2003b). R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model. Behavioural Pharmacology 14, 465-470.
32. Sidhu J, Priskorn M, Poulsen M, Segonzac A, Grollier G, Larsen F (1997). Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 9, 686-692.
33. Suhara T, Sudo Y, Yoshida K, Okubo Y, Fukuda H, Obata T, Yoshikawa K, Suzuki K, Sasaki Y (1998). Lung as reservoir for antidepressants in pharmacokinetic drug interactions. Lancet 351, 332-335.
34. Tarkiainen J, Vercouillie J, Emond P, Sandell J, Hiltunen J, Frangin Y, Guilloteau D, Halldin C (2001). Carbon-11 labelling of MADAM in two different positions : a highly selective PET radioligand for the serotonin transporter. Journal of Labelled Compounds & Radiopharmaceuticals 44, 1013-1023.
35. Vaswani M, Linda FK, Ramesh S (2003). Role of selective serotonin reuptake inhibitors in psychiatric disorders : a comprehensive review. Progress in Neuro-Psychopharmacology & Biological Psychiatry 27, 85-102.
36. Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, Heiss W (1994). The ECAT EXACT HR: performance of a new high resolution positron scanner. Journal of Computer Assisted Tomography 18, 110-118.